The medicine Retevmo contains Selpercatinib for treating patients with metastatic RET fusion-positive non-small cell lung cancer, advanced or metastatic RET-mutant medullary thyroid cancer and advanced or metastatic RET fusion-positive thyroid….
The medicine Retevmo contains Selpercatinib, a kinase inhibitor used in the treatment of patients who have metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer (namely RET-Mutant Medullary….
The drug Venetoclax is a BCL-2 inhibitor that is recommended by healthcare professionals in treating patients with chronic lymphocytic leukemia (CLL) with 17p deletion. This drug is sold under the….
The drug Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. Healthcare professionals recommend using this drug in treating patients with chronic lymphocytic leukemia (CLL)….